Connor, Clark & Lunn Investment Management (CC&L)’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $31.3M | Buy |
|
|||||
|
2025
Q1 | $6.18M | Sell |
|
|||||
|
2024
Q4 | $8.68M | Buy |
|
|||||
|
2024
Q3 | $1.98M | Buy |
|
|||||
|
2024
Q2 | $307K | Buy |
|
|||||
|
2024
Q1 | – | Sell |
|
|||||
|
2023
Q4 | $3.68M | Sell |
|
|||||
|
2023
Q3 | $7.88M | Sell |
|
|||||
|
2023
Q2 | $15.3M | Sell |
|
|||||
|
2023
Q1 | $24.4M | Buy |
|
|||||
|
2022
Q4 | $21.1M | Sell |
|
|||||
|
2022
Q3 | $21M | Sell |
|
|||||
|
2022
Q2 | $20.9M | Buy |
|
|||||
|
2022
Q1 | $19.6M | Buy |
|
|||||
|
2021
Q4 | $4.44M | Buy |
|
|||||
|
2021
Q2 | – | Sell |
|
|||||
|
2021
Q1 | $446K | Buy |
|
|||||
|
2020
Q4 | – | Sell |
|
|||||
|
2020
Q3 | $1.01M | Buy |
|
|||||
|
2018
Q4 | – | Sell |
|
|||||
|
2018
Q3 | $366K | Buy |
|
|||||
|
2015
Q2 | – | Sell |
|
|||||
|
2015
Q1 | $1.41M | Sell |
|
|||||
|
2014
Q4 | $1.02M | Buy |
|
|||||
|
2014
Q1 | – | Sell |
|
|||||
|
2013
Q4 | $364K | Sell |
|
|||||
|
2013
Q3 | $1.07M | Buy |
|
|||||
|
2013
Q2 | $353K | Buy |
|